Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma

Coppin, 2005, Immunotherapy for advanced renal cell cancer, Cochrane Database Syst Rev, CD001425

Jonasch, 2001, Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities, Oncologist, 6, 34, 10.1634/theoncologist.6-1-34

Schwartz, 2002, Managing toxicities of high-dose interleukin-2, Oncology (Williston Park), 16, 11

Sablin, 2007, Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients, J Clin Oncol, 25, 244s

Rini, 2007, Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib, J Clin Oncol, 25, 242s

Rixe, 2007, Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study, Lancet Oncol, 8, 975, 10.1016/S1470-2045(07)70285-1

Escudier, 2009, Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV)+interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC), J Clin Oncol, 27, 239s

Rini, 2009, Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206, J Clin Oncol, 27, 798s

Motzer, 2008, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, Lancet, 372, 449, 10.1016/S0140-6736(08)61039-9

Sternberg, 2009, A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC), J Clin Oncol, 27, 240s

Escudier, 2009, Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial, J Clin Oncol, 27, 3312, 10.1200/JCO.2008.19.5511

Motzer, 2009, Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma, J Clin Oncol, 27, 3584, 10.1200/JCO.2008.20.1293

Hudes, 2007, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, 356, 2271, 10.1056/NEJMoa066838

Herbst, 1998, Evaluation of microvessel density by computerised image analysis in human renal cell carcinoma. Correlation to pT category, nuclear grade, proliferative activity and occurrence of metastasis, J Cancer Res Clin Oncol, 124, 141, 10.1007/s004320050147

Jacobsen, 2004, Expression of vascular endothelial growth factor protein in human renal cell carcinoma, BJU Int, 93, 297, 10.1111/j.1464-410X.2004.04605.x

Kaelin, 2007, The von Hippel–Lindau tumor suppressor protein and clear cell renal carcinoma, Clin Cancer Res, 13, 680s, 10.1158/1078-0432.CCR-06-1865

Kaelin, 2005, The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing, Biochem Biophys Res Commun, 338, 627, 10.1016/j.bbrc.2005.08.165

Folkman, 2005, Antiangiogenesis agents, 2865

Verheul, 2000, The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors, Clin Breast Cancer, 1, S80, 10.3816/CBC.2000.s.015

Jain, 2006, Lessons from phase III clinical trials on anti-VEGF therapy for cancer, Nat Clin Pract Oncol, 3, 24, 10.1038/ncponc0403

Augustin, 2009, Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system, Nat Rev Mol Cell Biol, 10, 165, 10.1038/nrm2639

Lobov, 2002, Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo, Proc Natl Acad Sci USA, 99, 11205, 10.1073/pnas.172161899

Baluk, 2005, Cellular abnormalities of blood vessels as targets in cancer, Curr Opin Genet Dev, 15, 102, 10.1016/j.gde.2004.12.005

Willett, 2004, Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer, Nat Med, 10, 145, 10.1038/nm988

Presta, 1997, Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders, Cancer Res, 57, 4593

Kim, 1992, The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies, Growth Factors, 7, 53, 10.3109/08977199209023937

Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N Engl J Med, 349, 427, 10.1056/NEJMoa021491

Bukowski, 2007, Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer, J Clin Oncol, 25, 4536, 10.1200/JCO.2007.11.5154

Escudier, 2007, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, Lancet, 370, 2103, 10.1016/S0140-6736(07)61904-7

Rini B, Halabi S, Rosenberg J, et al. CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha monotherapy in metastatic renal cell carcinoma. In: Presented at Genitourinary Cancers Symposium; 2008. p. 267 [Abstract 350].

Avastin Summary of Product Characteristics (SmPC). 2008. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/avastin/avastin.htm.

Besse, 2010, Bevacizumab Safety in Patients with Central Nervous System Metastases, Clin Cancer Res, 16, 269, 10.1158/1078-0432.CCR-09-2439

Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med, 357, 2666, 10.1056/NEJMoa072113

Sandler, 2006, Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884

Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691

Carmeliet, 1996, Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele, Nature, 380, 435, 10.1038/380435a0

Ferrara, 1998, Vascular endothelial growth factor is essential for corpus luteum angiogenesis, Nat Med, 4, 336, 10.1038/nm0398-336

Wedge, 2005, AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer, Cancer Res, 65, 4389, 10.1158/0008-5472.CAN-04-4409

Rousseau, 2000, Integrating the VEGF signals leading to actin-based motility in vascular endothelial cells, Trends Cardiovasc Med, 10, 321, 10.1016/S1050-1738(01)00072-X

Koolwijk, 2001, Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro, Angiogenesis, 4, 53, 10.1023/A:1016637700638

Gerber, 1998, Et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation, J Biol Chem, 273, 30336, 10.1074/jbc.273.46.30336

Bates, 2001, Vascular endothelial growth factor increases Rana vascular permeability and compliance by different signalling pathways, J Physiol, 533, 263, 10.1111/j.1469-7793.2001.0263b.x

Porta, 2009, Tolerability of first-line therapy for metastatic renal cell carcinoma, Cancer Treat Rev, 35, 297, 10.1016/j.ctrv.2008.12.003

Kamba, 2007, Mechanisms of adverse effects of anti-VEGF therapy for cancer, Br J Cancer, 96, 1788, 10.1038/sj.bjc.6603813

Izzedine, 2007, Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension, Am J Kidney Dis, 50, 203, 10.1053/j.ajkd.2007.04.025

Bates, 2003, The role of vascular endothelial growth factor in wound healing, Int J Low Extrem Wounds, 2, 107, 10.1177/1534734603256626

Witzenbichler, 1998, Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia, Am J Pathol, 153, 381, 10.1016/S0002-9440(10)65582-4

Shay-Salit, 2002, VEGF receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells, Proc Natl Acad Sci USA, 99, 9462, 10.1073/pnas.142224299

Vaughn, 2008, Reversible posterior leukoencephalopathy syndrome in cancer, Curr Oncol Rep, 10, 86, 10.1007/s11912-008-0013-z

Patel, 2008, A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib, J Natl Cancer Inst, 100, 282, 10.1093/jnci/djm311

Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655

Scappaticci, 2007, Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab, J Natl Cancer Inst, 99, 1232, 10.1093/jnci/djm086

Fabbro, 2002, Protein kinases as targets for anticancer agents: from inhibitors to useful drugs, Pharmacol Ther, 93, 79, 10.1016/S0163-7258(02)00179-1

Christensen, 2007, A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities, Ann Oncol, 18, x3, 10.1093/annonc/mdm408

Chow, 2007, Sunitinib: from rational design to clinical efficacy, J Clin Oncol, 25, 884, 10.1200/JCO.2006.06.3602

Wilhelm, 2004, BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res, 64, 7099, 10.1158/0008-5472.CAN-04-1443

Bhargava, 2009, Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC), J Clin Oncol, 27, 242s

Sloan, 2008, Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy, Curr Opin Invest Drugs, 9, 1324

Sonpavde, 2008, Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma, Expert Opin Invest Drugs, 17, 253, 10.1517/13543784.17.2.253

Kumar, 2007, Pharmacokinetic–pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity, Mol Cancer Ther, 6, 2012, 10.1158/1535-7163.MCT-07-0193

Hu-Lowe, 2008, Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3, Clin Cancer Res, 14, 7272, 10.1158/1078-0432.CCR-08-0652

Tsai, 2006, Hand–foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma, J Clin Oncol, 24, 5786, 10.1200/JCO.2006.08.6868

Erber, 2004, Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms, FASEB J, 18, 338, 10.1096/fj.03-0271fje

Botchkareva, 2001, SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit, FASEB J, 15, 645, 10.1096/fj.00-0368com

Force, 2007, Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition, Nat Rev Cancer, 7, 3324, 10.1038/nrc2106

Schmidinger, 2008, Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma, J Clin Oncol, 26, 5204, 10.1200/JCO.2007.15.6331

Gerber, 2002, VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism, Nature, 417, 954, 10.1038/nature00821

Ramsden, 2000, Angiogenesis in the thyroid gland, J Endocrinol, 166, 475, 10.1677/joe.0.1660475

Chu, 2007, Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib, Lancet, 370, 2011, 10.1016/S0140-6736(07)61865-0

Yang, 2004, Bevacizumab for patients with metastatic renal cancer: an update, Clin Cancer Res, 10, 6367S, 10.1158/1078-0432.CCR-050006

Giantonio, 2007, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200, J Clin Oncol, 25, 1539, 10.1200/JCO.2006.09.6305

Tamaskar, 2008, Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib, Ann Oncol, 19, 265, 10.1093/annonc/mdm483

Houk, 2007, Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach, J Clin Oncol, 25, 241s

Mendel, 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship, Clin Cancer Res, 9, 327

Humar, 2002, Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling, FASEB J, 16, 771, 10.1096/fj.01-0658com

Wullschleger, 2006, TOR signaling in growth and metabolism, Cell, 124, 471, 10.1016/j.cell.2006.01.016

Abraham, 2007, The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy, Clin Cancer Res, 13, 3109, 10.1158/1078-0432.CCR-06-2798

Crouthamel, 2009, Mechanism and management of AKT inhibitor-induced hyperglycemia, Clin Cancer Res, 15, 217, 10.1158/1078-0432.CCR-08-1253

Aggarwal, 2006, Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs, Metabolism, 55, 794, 10.1016/j.metabol.2006.01.017

Albiges, 2009, Interstitial pneumonitis during RAD-001 treatment: incidence by blinded radiological analysis, Eur J Cancer Suppl, 7, 427, 10.1016/S1359-6349(09)71447-8

Pablo, 2009, Radiographic findings of drug-induced pneumonitis and clinical correlation in patients with advanced renal cell carcinoma treated with temsirolimus, Eur J Cancer Suppl, 7, 426, 10.1016/S1359-6349(09)71446-6

Pastore, 2008, The epidermal growth factor receptor system in skin repair and inflammation, J Invest Dermatol, 128, 1365, 10.1038/sj.jid.5701184

Klein, 2009, Targeting the EGFR and the PKB pathway in cancer, Curr Opin Cell Biol, 21, 185, 10.1016/j.ceb.2008.12.006

Letavernier, 2008, MToR inhibitors-induced proteinuria: mechanisms, significance, and management, Transplant Rev (Orlando), 22, 125, 10.1016/j.trre.2007.12.001

Anderson, 2009, Search for evidence-based approaches for the prevention and palliation of hand–foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs), Oncologist, 14, 291, 10.1634/theoncologist.2008-0237

Lacouture, 2008, Evolving strategies for the management of hand–foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib, Oncologist, 13, 1001, 10.1634/theoncologist.2008-0131

Patel, 2009, Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma, Clin Genitourin Cancer, 7, 24, 10.3816/CGC.2009.n.004

Patnaik, 2007, A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies, J Clin Oncol, 25, 141s

Cen, 2009, A phase I study of everolimus plus sorafenib in patients with metastatic renal cell carcinoma (mRCC), J Clin Oncol, 27

Kroog, 2009, Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma, J Clin Oncol, 27, 243s

Harzstark, 2009, A phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma, J Clin Oncol, 27, 259s

Ryan CW, Curti BD, Pattee KJ, Besaw L, Beer TM, Fisher B. A dose-escalation phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC). In: Presented at 2008 Genitourinary Cancers Symposium, San Francisco, CA; 2008. p. 267 [Abstract 361].

Whorf, 2008, Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC), J Clin Oncol, 26, 252s

Merchan, 2009, Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): safety and activity in RTKI refractory RCC patients, J Clin Oncol, 27, 244s

Sosman, 2008, Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC), J Clin Oncol, 26, 252s

Feldman, 2009, Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma, J Clin Oncol, 27, 1432, 10.1200/JCO.2008.19.0108

Clinical study results – Genentech. http://clinicalstudyresults.gene.com/avf4167g.pdf [serial online] 2009.

Cooney, 2008, Sunitinib and bevacizumab in advanced solid tumors: a phase I trial, J Clin Oncol, 26, 160s

Sablin, 2009, Sequential sorafenib and sunitinib for renal cell carcinoma, J Urol, 182, 29, 10.1016/j.juro.2009.02.119

Rini, 2008, Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma, J Clin Oncol, 26, 3743, 10.1200/JCO.2007.15.5416

Dudek, 2009, Sequential therapy with sorafenib and sunitinib in renal cell carcinoma, Cancer, 115, 61, 10.1002/cncr.24009